British research conducted under a European project have highlighted the role of antibodies produced by the joints affected by rheumatoid arthritis.New drug target for treating arthritis
The role of antibodies in the disease process would explain why the drugs suppressing the B cells, producing antibodies, fail to curb the disease. So far ACPA antibodies were associated to a more severe form of maladie.
People with rheumatoid arthritis produce an antibody called ACPA promoting the development of the disease. The enzyme cytidine deaminase (AID or protein) is cited as potential target for new treatments because the structures containing the AID are surrounded by B cells producing antibodies.
Rheumatoid arthritis, autoimmune disease that attacks the joints by inflammatory and destructive, currently has no known cure.
This study is the result of a five-year work on the project Innochem on the development of new therapeutic strategies against autoimmunity and chronic inflammation, funded by the European Union.
Related Post :
New Treatment Of Rheumatoid Arthritis With Anti-Inflammatory
Group of orthopedic surgeons Dusseldorf (Germany) has discovered a new class of compounds biological for the treatment of rheumatoid arthritis.
Rheumatoid Arthritis Therapy Type
Rheumatoid Arthritis Therapy Type. Rheumatoid Arthritis Therapy, Symptoms and Drugs Rheumatoid arthritis UK society giving information on rheumatoid
Vitamin D Could Reduce Rheumatoid Arthritis Risk
Vitamin D may have beneficial effects on rheumatoid arthritis, according to a study published
Living with Psoriatic Arthritis Fatigue
Living with Psoriatic Arthritis Fatigue, how resolve psoriatic arthritis fatigue and stress caused by the condition.
No comments:
Post a Comment